As Mr. Herder referenced and you now are referencing, there are no results-based data, or very little in my understanding, with regard to making the decisions concerning orphan drugs and whether or not they would be included.
Mr. Herder, you said that when we make these formulary decisions going forward, they should not be politically based, but results based. If we don't have those results for orphan drugs, then how are we to make those decisions? Are you suggesting that orphan drugs should not be included in the formulary? If that isn't what you are suggesting, then I wonder where we draw the line in terms of what is going to be included and what is not going to be included in the formulary going forward.
I would ask this question of both Dr. Wong-Rieger and Mr. Herder.